| Name | isocorydine hydrochloride | 
|---|---|
| Synonyms | 
                                
                                artabotrin
                                
                                
                                 1,2,10-Trimethoxy-6aa-aporphin-11-ol d-isocorydine (6aS)-1,2,10-Trimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-ol 6aα-Aporphin-11-ol, 1,2,10-trimethoxy- luteanin isocorydine (S)-5,6,6a,7-Tetrahydro-1,2,10-trimethoxy-6-methyl-4H-dibenzo[de,g]quinolin-11-ol iso-Corydine 4H-Dibenzo[de,g]quinolin-11-ol, 5,6,6a,7-tetrahydro-1,2,10-trimethoxy-6-methyl-, (6aS)- LUTEANINE  | 
                        
| Description | Isocorydine is isolated from Dicranostigma leptopodum (Maxim.) Fedde (DLF). Isocorydine combines with Doxorubicin (DOX) has a promising potential to eradicate hepatocellular carcinoma (HCC)[1]. | 
|---|---|
| Related Catalog | |
| In Vitro | Isocorydine (0-400 ug/ml; 48 hours) show a significant decrease in the IC50 for ICD and DOX, the CI values are 0.605, 0.644, 0.804, and 0.707 respectively for Huh-7, Hep-G2, SNU-449 and SNU-387[1]. Isocorydine (0-400 ug/ml; 48 hours) abrogates DOX-induced upregulation of mesenchymal markers and the downregulation of epithelial markers in human HCC cell lines[1]. Cell Viability Assay[1] Cell Line: Huh-7, Hep-G2 , SNU-387, SNU-449 cells Concentration: 0-400 ug/ml Incubation Time: 24 hours Result: Had a higher cytotoxicity in HCC cells in comparison to ICD or DOX alone. Western Blot Analysis[1] Cell Line: Huh-7, Hep-G2 , SNU-387, SNU-449 cells Concentration: Incubation Time: 24 hours Result: Downregulated protein levels of Claundin-1 and E-cadherin. | 
| In Vivo | Isocorydine (intraperitoneal injection; 0.4 mg/kg; every 2 days for 2 weeks) retards the tumor growth, but the combined treatment of Doxorubicin (DOX) or ICD significantly inhibits tumor growth[1]. Animal Model: Female nude mice[1] Dosage: 0.4 mg/ml Administration: Injected intraperitoneally every 2 days for 2 weeks Result: Combined treatment of isocorydine and DOX showed a promising potential to eradicate HCC. | 
| References | 
| Density | 1.2±0.1 g/cm3 | 
|---|---|
| Boiling Point | 506.1±50.0 °C at 760 mmHg | 
| Melting Point | 216-220ºC(lit.) | 
| Molecular Formula | C20H23NO4 | 
| Molecular Weight | 341.401 | 
| Flash Point | 259.9±30.1 °C | 
| Exact Mass | 341.162720 | 
| PSA | 51.16000 | 
| LogP | 3.09 | 
| Vapour Pressure | 0.0±1.4 mmHg at 25°C | 
| Index of Refraction | 1.604 | 
| Storage condition | -20℃ | 
                                CHEMICAL IDENTIFICATION
 
 
 
 
 
 
 
 HEALTH HAZARD DATAACUTE TOXICITY DATA
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  | 
                        
| WGK Germany | 3 | 
|---|---|
| RTECS | CE1057950 | 
| Precursor 2 | |
|---|---|
| DownStream 3 | |